12 research outputs found
W1149 Impact of Enterocolono-MR in Patients With Crohn's Disease and Incomplete Endoscopy
Dissecting common and unique effects of anti-alpha4beta7 and anti-tumor necrosis factor treatment in ulcerative colitis
Background and Aims:Vedolizumab is an anti-α4β7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the unique mechanisms of action of vedolizumab in UC patients, we compared its effects to those induced by anti-tumour necrosis factor [TNF]. Methods:patients with active UC [endoscopic Mayo score >1] starting vedolizumab [n = 33] or anti-TNF [n = 45] and controls [n = 22] were included. Colon biopsies [at weeks 0, 14 and 46] and blood samples [at weeks 0, 2, 6, 14, 30 and 46] were used for cell phenotyping, transcriptional analysis [qPCR], and to measure receptor occupancy. Results:Vedolizumab, in contrast to anti-TNF, significantly reduced the proportion of α4β7+ cells within intestinal T subsets while preserving the percentage of α4β7+ plasma cells. The marked decrease in α4β7 did not change the percentage of colonic αEβ7+ cells [at 46 weeks]. Both vedolizumab and anti-TNF significantly downregulated inflammation-related genes in the colon of responders [Mayo score < 2]. Moreover, both treatments significantly decreased the percentage of intestinal, but not blood, total lymphocytes [T and plasma cells], as well as the proportion of α4β1+ cells within intestinal T lymphocytes. Conclusions:Our data show that while vedolizumab and anti-TNF block two unrelated targets, they induce remarkably similar effects. On the other hand, vedolizumab's unique mechanism of action relies on blocking intestinal trafficking of α4β7 T cells, despite effectively binding to B and plasma cells that express α4β7
Reliability of measuring ileo-colonic disease activity in Crohn’s Disease by magnetic resonance enterography
Background: Magnetic resonance enterography is increasingly utilized for assessment of luminal Crohn's disease activity. The Magnetic Resonance Index of Activity and the London Index are the most commonly used outcome measures in clinical trials. We assessed the reliability of these indices and several additional items.
Methods: A consensus process clarified scoring conventions and identified additional items based on face validity. Four experienced radiologists evaluated 50 images in triplicate, in random order, at least 1 month apart, using a central image management system. Intra-and interrater reliability were assessed by calculating and comparing intraclass correlation coefficients.
Results: Intrarater intraclass correlation coefficients (95% confidence intervals) for the Magnetic Resonance Index of Activity, London, and London "extended" indices and a visual analogue scale were 0.89 (0.84 to 0.91), 0.87 (0.83 to 0.90), 0.89 (0.85 to 0.92), and 0.86 (0.81 to 0.90). Corresponding interrater intraclass correlation coefficients were 0.71 (0.61 to 0.77), 0.67 (0.55 to 0.75), 0.70 (0.61 to 0.76), and 0.71 (0.62 to 0.77). Reliability for each index was greatest in the terminal ileum and poorest in the rectum. All 3 indices were highly correlated with the visual analogue scale; 0.79 (0.71 to 0.85), 0.78 (0.71 to 0.84), and 0.79 (0.72 to 0.85) for the Magnetic Resonance Index of Activity, London, and the London "extended" indices, respectively.
Conclusions: "Substantial" interrater reliability was observed for all 3 indices. Future studies should assess responsiveness to treatment in order to confirm their utility as evaluative indices in clinical trials and clinical practice
Disability in newly diagnosed patients with Crohn´s Disease (CD): initial results from the prospective CROCO (Crohn´s Disease Cohort) Study
peer reviewe
S1108 Hepatitis B and C Reactivation in Inflammatory Bowel Disease Patients Treated with Immunosuppressive Therapy. A Nationwide Multicenter Study
W1193 Safety of Thiopurine Therapy in Inflammatory Bowel Disease (IBD): Long-Term Follow-up Study of 3,900 Patients
Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease
peer reviewedBackground: Crohn’s disease (CD) progression can lead to bowel damage (BD) and disability. However, the longitudinal characterization of BD and
disability in early CD patients remains limited.
Methods: The Crohn´s Disease Cohort (CROCO) is a multicentre, European cohort study of newly diagnosed CD patients (<12 months following
diagnosis) intended to prospectively characterize BD progression and disability. At one year following inclusion (Y1), BD progression was evaluated
using the Lémann Index (LI). Magnetic resonance enterography was completed by all patients, with additional endoscopy and/or pelvic MRI
based on disease location. Absence of BD was defined as a LI=0, and any presence of bowel damage was indicated by LI>0. Disability was assessed
using the validated IBD-disability index (IBD-DI) encompassing various domains. We report the LI at Y1 and its association with significant disease
features and with the IBD-DI.
Results: Among the 261 included patients, 135 have completed the Y1 visit, with 100 having their LI calculated [57% male, median age at diagnosis
of 36 years old (IQR 26-48)]. Most patients (90%) had ileal or ileocolonic involvement, 68% had inflammatory phenotype, and 11% had perianal
disease. At inclusion, 7% of patients had undergone surgery (5 intestinal and 2 perianal), and 53% had initiated biological therapy within the first
year of disease, primarily anti-TNF in mono or combination therapy. Of those with stricturing (B2) or penetrating (B3) behaviour, 77% and 79%,
respectively, were on anti-TNF therapy. Overall, 61% of the patients exhibited some degree of BD (LI>0), yet the median LI at Y1 was low [0.6
(IQR 0-2)]. Univariate analysis revealed an association between the presence of any bowel damage at Y1 and disease behaviour at inclusion (B2
OR 3.33, 95%CI 0.84-13.18 and B3 OR 8.5, 95%CI 1.82, 39.66; p<0.01). Additionally, there was a significant association with anti-TNF therapy
(OR 2.88, 95%CI 1.24-6.66, p=0.012). In a multivariate logistic model, only older age at diagnosis appeared protective against any BD (Table 1).
Among those evaluated for the LI, 84 completed the IBD-DI at Y1. The median IBD-DI was 17.3 (IQR 10.7-32.6) and 30% experienced moderateto-
severe disability (IBD-DI>35). No association was observed between LI and IBD-DI at Y1 (OR 1.09, 95%CI 0.39-3.04, p=0.86) and there were
no differences in the median LI across disability categories (p=0.67) (Figure 1).
Conclusion: In a cohort of newly diagnosed CD patients, one-third exhibited no bowel damage as per the LI evaluation. For those presenting any
degree of damage, the global LI remained low. No association was found with disability assessed by the IBD-DI. These data add to the growing
concept that early disease represents a window of opportunity
Microbiological diagnosis of invasive candidiasis
Background Candida spp. are responsible for opportunistic fungal infections inpatients with known risk factors. Clinical diagnosis of invasive candidiasisis difficult because clinical features and symptoms are usually non-specific. The problem also represents isolation of pathogenic yeasts from sterile site which lacks desired level of sensitivity. Conclusions Confirming diagnosis of invasive candidiasis requires isolation and identification of pathogenic fungi from a normally sterile site. Identification of Candida spp. is increasingly important for several reasons: Candida spp. differ in their susceptibility to antifungal agents, species-specific identification is relevant for epidemiological purposes and the severity of clinical manifestations differs depending on the infecting species. Serological tests can also be helpful for diagnosis of invasive candidiasis, among which direct detection of antigens is of most value. Newer techniques of molecular biology hold promise because of their high sensitivity and specificity, but are not yet standardized and clinically validated
Automatic Application of Software Countermeasures Against Physical Attacks
International audienceWhile the number of embedded systems is continuously increasing, securing software against physical attacks is costly and error-prone. Several works proposed solutions that automatically insert protections against these attacks in order to reduce this cost and this risk of error. In this chapter, we present a survey of existing approaches and classify them by the level at which they apply the countermeasure. We consider three different levels: the source code level, the compilation level, and the assembly/binary level. We explain the advantages and disadvantages of each level considering different criteria. Finally, we encourage future works to take compilation into account when designing tools, to consider the problem of combining countermeasures, as well as the interactions between countermeasures and compiler optimisations. Going one step further, we encourage future works to imagine how compilation could be modified or redesigned to optimise both performance and security